These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 18612019)

  • 1. What potential biologic treatments are available for osteolysis?
    Schwarz EM;
    J Am Acad Orthop Surg; 2008; 16 Suppl 1():S72-5. PubMed ID: 18612019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Are biologic treatments a potential approach to wear- and corrosion-related problems?
    Smith RL; Schwarz EM
    Clin Orthop Relat Res; 2014 Dec; 472(12):3740-6. PubMed ID: 24993143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What other biologic and mechanical factors might contribute to osteolysis?
    Greenfield EM; Bechtold J;
    J Am Acad Orthop Surg; 2008; 16 Suppl 1():S56-62. PubMed ID: 18612015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spinal implant debris-induced osteolysis.
    Hallab NJ; Cunningham BW; Jacobs JJ
    Spine (Phila Pa 1976); 2003 Oct; 28(20):S125-38. PubMed ID: 14560184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cellular and molecular biology of periprosthetic osteolysis.
    Purdue PE; Koulouvaris P; Potter HG; Nestor BJ; Sculco TP
    Clin Orthop Relat Res; 2007 Jan; 454():251-61. PubMed ID: 16980902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Periprosthetic osteolysis: genetics, mechanisms and potential therapeutic interventions.
    Noordin S; Masri B
    Can J Surg; 2012 Dec; 55(6):408-17. PubMed ID: 22992398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of periprosthetic osteolysis in total joint arthroplasty: an emphasis on host factors and future directions.
    Beck RT; Illingworth KD; Saleh KJ
    J Orthop Res; 2012 Apr; 30(4):541-6. PubMed ID: 21922533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aseptic loosening of total joint replacements: mechanisms underlying osteolysis and potential therapies.
    Abu-Amer Y; Darwech I; Clohisy JC
    Arthritis Res Ther; 2007; 9 Suppl 1(Suppl 1):S6. PubMed ID: 17634145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MMP-9 inhibition suppresses wear debris-induced inflammatory osteolysis through downregulation of RANK/RANKL in a murine osteolysis model.
    Chen D; Zhang X; Guo Y; Shi S; Mao X; Pan X; Cheng T
    Int J Mol Med; 2012 Dec; 30(6):1417-23. PubMed ID: 23027468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Research progress on wear particles and periprosthetic osteolysis after artificial joint replacement].
    Jiang YJ; Wu LG
    Zhongguo Gu Shang; 2016 Oct; 29(10):968-972. PubMed ID: 29285918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-TNF-alpha therapy as a clinical intervention for periprosthetic osteolysis.
    Schwarz EM; Looney RJ; O'Keefe RJ
    Arthritis Res; 2000; 2(3):165-8. PubMed ID: 11094423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative small-animal surrogate to evaluate drug efficacy in preventing wear debris-induced osteolysis.
    Schwarz EM; Benz EB; Lu AP; Goater JJ; Mollano AV; Rosier RN; Puzas JE; Okeefe RJ
    J Orthop Res; 2000 Nov; 18(6):849-55. PubMed ID: 11192243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How has the biologic reaction to wear particles changed with newer bearing surfaces?
    Jacobs JJ; Campbell PA; T Konttinen Y;
    J Am Acad Orthop Surg; 2008; 16 Suppl 1():S49-55. PubMed ID: 18612014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scutellarin inhibits RANKL-mediated osteoclastogenesis and titanium particle-induced osteolysis via suppression of NF-κB and MAPK signaling pathway.
    Zhao S; Sun Y; Li X; Wang J; Yan L; Zhang Z; Wang D; Dai J; He J; Wang S
    Int Immunopharmacol; 2016 Nov; 40():458-465. PubMed ID: 27728897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there another possible approach to inhibit wear particles-induced inflammatory osteolysis?
    Liu YP; Yu GR; Li K; Yuan F
    Med Hypotheses; 2011 Feb; 76(2):280-2. PubMed ID: 21067868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alteration of the RANKL/RANK/OPG System in Periprosthetic Osteolysis with Septic Loosening.
    Wang L; Dai Z; Xie J; Liao H; Lv C; Hu Y
    Inflammation; 2016 Feb; 39(1):218-227. PubMed ID: 26294373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Periprosthetic osteolysis: a narrative review.
    Marmotti A; Messina D; Cykowska A; Beltramo C; Bellato E; Colombero D; Agati G; Mangiavini L; Bruzzone M; Dettoni F; Peretti GM; Castoldi F
    J Biol Regul Homeost Agents; 2020; 34(4 Suppl. 3):405-417. Congress of the Italian Orthopaedic Research Society. PubMed ID: 33261304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-inflammatory drug-eluting implant model system to prevent wear particle-induced periprosthetic osteolysis.
    Rivera MC; Perni S; Sloan A; Prokopovich P
    Int J Nanomedicine; 2019; 14():1069-1084. PubMed ID: 30804671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. What patient and surgical factors contribute to implant wear and osteolysis in total joint arthroplasty?
    Tsao AK; Jones LC; Lewallen DG;
    J Am Acad Orthop Surg; 2008; 16 Suppl 1():S7-13. PubMed ID: 18612018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Jatrorrhizine Hydrochloride Suppresses RANKL-Induced Osteoclastogenesis and Protects against Wear Particle-Induced Osteolysis.
    Li H; Wang J; Sun Q; Chen G; Sun S; Ma X; Qiu H; Liu X; Xu L; Liu M
    Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30469456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.